Biggest News Aggregation in the World
📰 Evaluate Efficacy News

Evaluate Efficacy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Evaluate Efficacy. Real-time updates on events, politics, business and more.

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Czech Republic United States Parag Mahanti David Soergel Prnewswire Novartis Marianne Silkj

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
United States Czech Republic Imke Kappes Marlena Abdinoor David Soergel Michael Meo

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science